Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 5.6%

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) traded down 5.6% on Monday . The company traded as low as $7.91 and last traded at $7.94. 2,262,832 shares were traded during trading, a decline of 66% from the average session volume of 6,719,053 shares. The stock had previously closed at $8.41.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. KeyCorp upped their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an "overweight" rating in a report on Monday, March 4th. TD Cowen initiated coverage on Recursion Pharmaceuticals in a research note on Friday, January 26th. They issued a "market perform" rating on the stock. Finally, Needham & Company LLC restated a "buy" rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals has an average rating of "Hold" and an average price target of $12.75.

Recursion Pharmaceuticals Trading Down 7.4 %

The company has a market cap of $1.83 billion, a PE ratio of -5.03 and a beta of 0.76. The firm has a 50 day moving average of $10.91 and a two-hundred day moving average of $9.11.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The company had revenue of $10.89 million for the quarter, compared to the consensus estimate of $12.37 million. On average, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, insider Shafique Virani sold 18,000 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $10.93, for a total transaction of $196,740.00. Following the sale, the insider now directly owns 136,748 shares in the company, valued at approximately $1,494,655.64. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, insider Shafique Virani sold 18,000 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $10.93, for a total transaction of $196,740.00. Following the transaction, the insider now directly owns 136,748 shares of the company's stock, valued at approximately $1,494,655.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $8.82, for a total value of $100,962.54. Following the transaction, the director now directly owns 7,241,308 shares in the company, valued at $63,868,336.56. The disclosure for this sale can be found here. In the last three months, insiders have sold 384,701 shares of company stock worth $4,026,461. Insiders own 19.96% of the company's stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Profund Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 209.0% during the 3rd quarter. Profund Advisors LLC now owns 184,235 shares of the company's stock valued at $1,409,000 after buying an additional 124,621 shares during the period. Citigroup Inc. raised its holdings in Recursion Pharmaceuticals by 165.3% in the 3rd quarter. Citigroup Inc. now owns 470,512 shares of the company's stock worth $3,599,000 after purchasing an additional 293,174 shares during the period. Pathstone Family Office LLC bought a new position in Recursion Pharmaceuticals in the 3rd quarter worth $93,000. UBS Group AG raised its holdings in Recursion Pharmaceuticals by 103.1% in the 3rd quarter. UBS Group AG now owns 342,679 shares of the company's stock worth $2,621,000 after purchasing an additional 173,954 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in Recursion Pharmaceuticals by 1,479.8% in the 3rd quarter. Principal Financial Group Inc. now owns 645,475 shares of the company's stock worth $4,938,000 after purchasing an additional 604,618 shares during the period. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.